In addition to testing performance at the natural rate of HER2+, we hypothesize there may be overexpressed protein markers that affect a higher fraction of tumors, i.e., an overexpressed marker present in all luminal breast tumors. The gene discussed is ERBB2; the disease is breast neoplasm.